Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported to act as an agonist of the vanilloid 1 channel in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol has also been reported to have potential as an antipsychotic. We investigated the effect of cannabidiol on sensorimotor gating deficits in mice induced by the noncompetitive NMDA receptor antagonist, MK-801. Sensorimotor gating is deficient in psychotic disorders such as schizophrenia and may be reliably measured by prepulse inhibition (PPI) of the startle response in rodents and humans. MK-801 (0.3-1 mg/kg i.p.) dose dependently disrupted PPI while cannabidiol (1-15 mg/kg i.p.), when administered with vehicle, had no effect on PPI. Cannabidiol (5 mg/kg i.p.) successfully reversed disruptions in PPI induced by MK-801 (1 mg/kg i.p.), as did the atypical antipsychotic clozapine (4 mg/kg i.p.). Pretreatment with capsazepine (20 mg/kg i.p.) prevented the reversal of MK-801-induced disruption of PPI by cannabidiol, providing preliminary evidence that TRPV1 receptors are involved in the reversal of MK-801-induced sensorimotor gating deficits by cannabidiol.
INTRODUCTION
Cannabidiol is a nonpsychoactive constituent of the Cannabis sativa plant. The major psychoactive Cannabis constituent D
9
-tetrahydrocannabinol (D 9 -THC) activates at least two cannabinoid receptors, CB 1 and CB 2 , which are coupled to G-proteins (Howlett et al, 2002) . Unlike D 9 -THC, cannabidiol has very weak affinity for CB 1 and CB 2 receptors (Bisogno et al, 2001 ) and does not alter neural uptake of amine neurotransmitters such as dopamine and 5-HT (Hershkowitz and Szechtman, 1979) or excite dopaminergic nerve cell firing (French et al, 1997) . Cannabidiol acts as a full agonist in vitro at the transient receptor potential vanilloid receptor (TRPV1), with desensitization and maximal stimulation similar to the prototypical TRPV1 agonist capsaicin (Bisogno et al, 2001) . Cannabidiol produces anti-inflammatory activity in rats mediated by TRPV1 but not by CB 1 or CB 2 receptors (Costa et al, 2004) , although it has been reported that it does not elicit the decrease in blood pressure or increased respiration usually produced by TRPV1 activation by capsaicin or by the endocannabinoid anandamide (McQueen et al, 2004) . Cannabidiol inhibits the hydrolysis of anandamide in mouse brain microsomes (Watanabe et al, 1996; Bisogno et al, 2001 ) and the carrier-mediated cellular uptake of anandamide in mast cells (Rakhshan et al, 2000; Bisogno et al, 2001) . This suggests that administration of cannabidiol may enhance the activity of endogenous anandamide, although the ( þ )-stereoisomer and other cannabidiol analogues display more potent inhibition of anandamide inactivation than the natural isomer, (À)-cannabidiol, used in most pharmacological investigations (Bisogno et al, 2001) .
Following the observation that cannabidiol reversed effects of D 9 -THC in humans, such as anxiety (Karniol et al, 1974; Zuardi et al, 1982) , research also examined its potential as an antipsychotic. Cannabidiol was reported to reverse some dopaminergic effects associated with apomorphine, such as stereotypy, prolactin secretion, and palpebral ptosis, while producing none of the catalepsy associated with 'typical' antipsychotics such as haloperidol (Zuardi et al, 1991) . This group later showed that cannabidiol increased Fos protein expression in the nucleus accumbens, but not in the striatum, indicating that cannabidiol produces neuronal activation in mesolimbic areas but not in motor control areas, and thus reinforcing the potential of cannabidiol to produce few unwanted motor effects (Guimaraes et al, 2004) . In humans, cannabidiol has been shown to reverse binocular depth inversion (a model of impaired visual perception during psychotic states) produced by the synthetic psychotropic cannabinoid nabilone (Leweke et al, 2000) . Cannabidiol was also efficacious in reducing psychotic symptoms and well tolerated in a clinical trial in a young schizophrenic female patient (Zuardi et al, 1995) . Most recently, cannabidiol was reported to reverse hyperlocomotion produced by amphetamine and ketamine in mice without producing catalepsy (Moreira and Guimaraes, 2005) .
Prepulse inhibition (PPI) is an animal model of sensorimotor gating, and is defined as the decrease in the acoustic startle response when a nonstartling prepulse is presented 30-500 ms before the startling pulse (Hoffman and Ison, 1980) . Sensorimotor gating is deficient in patients with psychotic disorders such as schizophrenia . Pharmacological models of disrupted PPI include dopaminergic and serotonergic activation and NMDA receptor antagonism and are excellent predictors of antipsychotic activity (Geyer et al, 2001) . Another form of startle response plasticity is habituation or the progressive reduction in response to an initially novel stimulus when the stimulus is presented repeatedly to a subject. The rate of habituation can be manipulated and is also reduced in psychotic disorders Bolino et al, 1992) . Based on observations in the literature of the antipsychotic potential of cannabidiol, the aim of the following experiments was to test the ability of cannabidiol to reverse disruptions in PPI induced by the noncompetitive NMDA receptor antagonist MK-801 and to determine the involvement of TRPV1 receptors in the effects of cannabidiol using the TRPV1 antagonist capsazepine. Clozapine was administered as a positive control to test the effects of a known antipsychotic against those of cannabidiol in reversing MK-801-induced disruptions.
METHODS

Animals and Housing
Male Swiss mice weighing between 25 and 30 g were used. The animals were housed in group cages and kept at 221C with a 12 h light-dark cycle. Food and drinking water were available ad libitum. The animal experimental protocols were approved by the Victorian College of Pharmacy, Monash University Animal Ethics Committee and conform to the guidelines set out by the National Health and Medical Research Council and all Australian Government regulations.
Drug Treatment
As a result of the number of interactions to be investigated, the injection schedule consisted of three injections. All animals were exposed to one treatment combination only. Experiment 2: Cannabidiol. Separate groups of mice were injected i.p. with vehicle (VEH1) followed 20 min later by an i.p. injection of cannabidiol (1, 5, or 15 mg/kg, CBD) and then followed 20 min later by a third i.p. injection of vehicle (0.1% ascorbic acid in distilled water, VEH3).
Experiment 3: Capsazepine þ cannabidiol þ MK-801. Separate groups of mice were injected i.p. with capsazepine (20 mg/kg, CPSZ) or vehicle (VEH1), followed 20 min later by i.p. cannabidiol (5 mg/kg, CBD) or vehicle (VEH2) and then followed by a third injection 20 min later of i.p. MK-801 (1 mg/kg) or vehicle (VEH3).
Experiment 4: Clozapine þ MK-801. Separate groups of mice were injected i.p. with vehicle (VEH1) followed 20 min later by an i.p. injection of clozapine (4 mg/kg, CLOZ) and then followed 20 min later by a third i.p. injection of MK-801 (1 mg/kg) or vehicle (VEH3).
This regime of three injections ensured that all mice received the same number of injections. Thus the data from
were reused in several analyses, as the appropriate vehicle control treatments were present.
Behavioural Testing
Startle reactivity was measured using two SR-LAB startle chambers (San Diego Instruments, San Diego, CA). The animal enclosures consisted of a perspex cylinder 40 mm in diameter on a platform connected to a piezoelectric accelerometer that detected movement within the cylinder. Above the cylinder was a speaker capable of producing white noise up to 120 dB(A) attached to programmable audio controls. The animal enclosure was located in an illuminated, ventilated, and sound-attenuated chamber.
All testing took place during the light phase. Animals were acclimatized in the startle chambers during three 0.5 h sessions: a morning and afternoon session on the day before testing and a morning session on the test day. In the afternoon of the test day, mice received three injections as described above. At 5 min after the third injection, mice were placed in the startle chamber. Mice were returned to their home cage between injections and before placement in the startle chamber.
After 5 min acclimatization to the background noise in the startle chamber of 70 dB(A), startle stimulus trials of 120 dB(A) intensity and 40 ms duration were applied, either alone or preceded by 100 ms with a prepulse of an intensity of 3, 6, or 12 dB(A) above background and 20 ms duration. Prepulse alone trials of 3, 6, or 12 dB(A) above background were also presented, as were trials containing no stimulus at all. A total of 10 trials of each type were presented in a pseudorandom order, with the intertrial interval varying in a random fashion from 8 to 22 s. An extra 10 pulse alone trials were presented in blocks at the beginning and end of each test session in order to observe habituation of the startle response and to scale down the initial startle response to a stable plateau. The whole body flinch (movement) elicited by the startle stimulus was detected by the accelerometer. PPI was calculated as a percentage of this startle response using the formula: % PPI ¼ (1À(startle amplitude after prepulse-pulse pair/startle amplitude after pulse only)) Â 100. A 0% PPI value indicates that there is no difference between the startle response (movement) to prepulse-plus-pulse trials and pulse alone trials. Positive values indicate the extent to which the startle response is diminished in the presence of a prepulse. Habituation was calculated according to the formula: % habituation ¼ (1À(startle amplitude at end of test session/startle amplitude at beginning of test session)) Â 100. A positive % habituation value indicates that a decrease in startle response has occurred over time.
Drugs
The following drugs were used: (À)-cannabidiol (Tocris), capsazepine (Sigma, Australia), clozapine (obtained from Dr Ben Capuano, Monash University), MK-801 (Sigma, Australia), Tween s 80 (Sigma, Australia), Cremophor s EL (BASF), and ascorbic acid (David Craig Galenicals, Australia).
The injection volume in each mouse for each drug was 10 ml/kg.
Statistical Analysis
A one-way ANOVA was used to compare both startle responses and % habituation between treatment groups in Experiments 1 and 2. When a main effect of treatment was detected (Po0.05), a Dunnett's vs control post hoc test was used to determine the level of significance for each treatment group. Differences between both startle responses and % habituation in Experiment 3 were measured using 2 Â 2 Â 2 ANOVA between treatment groups. Four post hoc individual planned contrasts between drug treatment combinations of interest were carried out using a ¼ 0.0125 (a ¼ 0.05/4).
A one-way repeated measures ANOVA was used to compare % PPI between groups in Experiments 1 and 2 (MK-801 and cannabidiol dose-response curves) with four levels of the between-subjects factor (0, 0.1, 0.3, or 1 mg/kg MK-801 or 0, 1, 5, or 15 mg/kg cannabidiol for Experiments 1 and 2, respectively) and prepulse intensity (3, 6, or 12 dB(A) above background) as the within-subjects factor. When a main effect of treatment on PPI was detected (Po0.05), a Dunnett's vs control post hoc test was performed to evaluate significant differences.
A 2 Â 2 Â 2 factorial ANOVA was used to compare % PPI between groups in Experiment 3. There were three betweensubjects factors (capsazepine or vehicle, cannabidiol or vehicle, and MK-801 or vehicle) and prepulse intensity (3, 6, or 12 dB(A) above background) was the within-subjects factor. When a main effect of treatment on PPI was detected (Po0.05), four post hoc individual planned contrasts between drug treatment combinations of interest were carried out using a ¼ 0.0125.
A 2 Â 2 repeated measures ANOVA was used to compare % PPI between groups in Experiment 4. There were two between-subjects factors (clozapine or vehicle and MK-801 or vehicle) and prepulse intensity (3, 6, or 12 dB(A) above background) was the within-subjects factor. Two post hoc individual planned contrasts were carried out using a ¼ 0.025 (a ¼ 0.05/2).
In all % PPI data analyses, when a drug treatment Â prepulse intensity interaction was detected, post hoc ANOVA was performed at each level of prepulse intensity.
Statistical analyses were performed with SPSS 11.5 for Windows (SPSS Inc.; Chicago, USA).
RESULTS
Experiment 1: MK-801
Statistical analysis revealed a significant effect on the startle response of VEH1 þ VEH2 þ MK 0.1 and VEH1 þ VEH2 þ MK 0.3, but not VEH1 þ VEH2 þ MK 1 treatment, in comparison with vehicle (F 3,23 ¼ 9.595, Po0.001, n ¼ 6-8, Figure 1a ).
There was a significant main effect of MK-801 on PPI (F 3,23 ¼ 8.044, Po0.01, n ¼ 6-8, Figure 1b ). There was a significant effect of prepulse intensity, reflecting increased PPI in the presence of greater prepulse intensities (F 2,46 ¼ 12.105, Po0.001, n ¼ 6-8). There was a significant treatment Â prepulse intensity interaction (F 6,46 ¼ 3.400, Po0.01, n ¼ 6-8). Post hoc ANOVA was performed to analyse % PPI data at each prepulse intensity, with Dunnett's test showing a significant effect at 12 dB for the VEH1 þ VEH2 þ MK 0.3 treatment group (F 3,23 ¼ 4.201, Po0.05, n ¼ 6-8) and at 6 and 12 dB for the VEH1 þ VEH2 þ MK 1 treatment group (F 3,23 ¼ 10.585, Po0.001, n ¼ 6-8).
There was no significant effect of MK-801 on habituation (P40.05, ANOVA, Table 1 ). These results indicate that MK-801 significantly increased the startle response at lower doses (0.1 and 0.3 mg/kg). MK-801 disrupted PPI at higher doses (0.3 and 1 mg/kg) but did not affect habituation.
Experiment 2: Cannabidiol
There was a significant effect on startle response of VEH1 þ CBD 1 þ VEH3 and VEH1 þ CBD 15 þ VEH3, but not VEH1 þ CBD 5 þ VEH3 treatment, in comparison with vehicle (F 3,21 ¼ 9.383, Po0.001, n ¼ 6-7, Figure 2a ).
There was no significant effect of cannabidiol (1, 5, or 15 mg/kg) on PPI (P40.05, Figure 2b ). There was a significant effect of prepulse intensity, reflecting increased PPI in the presence of greater prepulse intensities (F 1.55,32.51 ¼ 78.887, Po0.001, n ¼ 6-7).
There was no significant effect of cannabidiol on habituation (P40.05, ANOVA, Table 1 ).
These results indicate that cannabidiol significantly increased the startle response at the lowest and highest dose administered (1 and 15 mg/kg) but had no effect on PPI or habituation when administered with vehicle alone.
There was a significant main effect of capsazepine on startle response (F 1,42 ¼ 4.542, Po0.05, n ¼ 5-8) and a main effect of MK-801 on startle response (F 1,42 ¼ 5.698, Po0.05, n ¼ 5-8, Figure 3a ). There was a significant interaction between the effects of capsazepine and cannabidiol on startle response (F 1,42 ¼ 6.091, Po0.05, n ¼ 5-8). Individual planned comparisons did not reveal a significant effect of MK-801 on startle response compared with vehicle (P40.05, VEH1 þ VEH2 þ VEH3 vs VEH1 þ VEH2 þ MK 1) nor any effect of cannabidiol or capsazepine on the startle response in MK-801-treated mice (P40.05, CPSZ 20
There was a main effect of capsazepine (F 1,42 ¼ 4.919, Po0.05, n ¼ 5-8) and of MK-801 (F 1,42 ¼ 8.832, Po0.01, n ¼ 5-8, Figure 3b ) on PPI. There was a significant capsazepine Â cannabidiol interaction (F 1,42 ¼ 4.178, Po0.05, n ¼ 5-8). There was a significant effect of prepulse intensity, reflecting increased PPI in the presence of greater prepulse intensities (F 2,84 ¼ 38.071, Po0.001, n ¼ 5-8). There was also a significant prepulse intensity Â MK-801 interaction (F 2,84 ¼ 7.723, Po0.01, n ¼ 5-8) and a significant prepulse intensity Â capsazepine Â cannabidiol Â MK-801 interaction (F 2,84 ¼ 5.393, Po0.01, n ¼ 5-8).
Owing to the interactions between prepulse intensity and drug treatment, % PPI data were analysed by three-way ANOVA at each level of prepulse intensity. There was no significant effect of drug treatment at 3 dB. At 6 dB, there was a significant effect of MK-801 (F 1,42 ¼ 16.088, Po0.001, n ¼ 5-8) and a significant capsazepine Â cannabidiol interaction (F 1,42 ¼ 4.715, Po0.05, n ¼ 5-8). At 12 dB, there were significant effects of capsazepine (F 1,42 ¼ 6.147, Po0.05, n ¼ 5-8) and MK-801 (F 1,42 ¼ 8.507, Po0.01, n ¼ 5-8) and a significant capsazepine Â cannabidiol interaction (F 1,42 ¼ 5.150, Po0.05, n ¼ 5-8). At both 6 dB and 12 dB, the capsazepine Â cannabidiol Â MK-801 interaction approached significance (P ¼ 0.067 and P ¼ 0.052 respectively).
Individual planned comparisons between treatment groups at each level of prepulse intensity revealed significant differences in PPI between VEH1 þ VEH2 þ VEH3 and VEH1 þ VEH2 þ MK 1 at the 12 dB prepulse level (t 0.0125,28 ¼ 4.689, Po0.001), between VEH1 þ VEH2 þ MK 1 and VEH1 þ CBD 5 þ MK 1 at the 12 dB level (t 0.0125,28 ¼ 3.111, Po0.01), and between VEH1 þ CBD 5 þ MK 1 and CPSZ 20 þ CBD 5 þ MK 1 at the 6 dB (t 0.0125,28 ¼ 3.623, Po0.01) and 12 dB levels (t 0.0125,28 ¼ 2.946, Po0.01). There was no significant difference between CPSZ 20 þ VEH2 þ MK 1 and VEH1 þ VEH2 þ MK 1 at any of the three prepulse intensities (P40.05).
There were no significant main effects of capsazepine, cannabidiol, or MK-801 on % habituation (P40.05, Table 1 ). There was a significant capsazepine Â MK-801 interaction (F 1,42 ¼ 4.835, Po0.05, n ¼ 5-8, Table 1 ).
These results indicate that capsazepine, cannabidiol, and MK-801 administered with vehicle or in combination did not alter the startle response. The disruption in PPI induced by MK-801 (1 mg/kg) was significantly restored by cannabidiol (5 mg/kg) and this effect was reversed by pretreatment with capsazepine (20 mg/kg). Capsazepine alone did not reverse the MK-801-induced PPI disruption.
Experiment 4: Clozapine þ MK-801
There was a main effect of clozapine on startle response (F 1,22 ¼ 5.306, Po0.05, n ¼ 5-8, Figure 4a ). The effect of MK-801 on startle response approached significance (P ¼ 0.069) but there was no significant clozapine Â MK-801 interaction (P40.05). However, post hoc analysis revealed no significant difference in startle response between the VEH1 þ VEH2 þ VEH3 and either the VEH1 þ CLOZ 4 þ VEH3 or the VEH1 þ CLOZ 4 þ MK 1 treatment groups.
There was a main effect of MK-801, but not clozapine, on PPI (F 1,22 ¼ 5.034, Po0.05, n ¼ 5-8, Figure 4b ). There was a significant clozapine Â MK-801 interaction (F 1,22 ¼ 8.305, Po0.01, n ¼ 5-8). There was a significant effect of prepulse intensity, reflecting increased PPI in the presence of greater prepulse intensities (F 2,44 ¼ 20.566, Po0.001, n ¼ 5-8). There was also a significant prepulse intensity Â clozapine interaction (F 2,44 ¼ 3.883, Po0.05, n ¼ 5-8).
Post hoc three-way ANOVA was performed to analyse % PPI data at each level of prepulse intensity. At 6 and 12 dB, there were significant clozapine Â MK-801 interactions (F 1,22 ¼ 4.803, Po0.05 and F 1,22 ¼ 7.471, Po0.05, respectively, n ¼ 5-8). Individual planned comparisons at each level of prepulse intensity revealed significant differences in PPI between VEH1 þ VEH2 þ VEH3 and VEH1 þ VEH2 þ MK 1 at the 12 dB prepulse level (t 0.025,19 ¼ 4.689, Po0.001) and between VEH1 þ VEH2 þ MK 1 and VEH1 þ CLOZ 4 þ MK 1 at the 6 dB (t 0.025,19 ¼ 3.335, Po0.01) and 12 dB levels (t 0.025,19 ¼ 3.275, Po0.01). There was a main effect of MK-801, but not clozapine, on habituation (F 1,22 ¼ 6.156, Po0.05, n ¼ 5-8, Table 1 ) but there was no significant clozapine Â MK-801 interaction (P40.05). However, post hoc analysis revealed no significant difference in habituation between the VEH1 þ VEH2 þ VEH3 and either the VEH1 þ VEH2 þ MK 1 or the VEH1 þ CLOZ 4 þ MK 1 treatment groups.
These results show that clozapine (4 mg/kg) decreased the startle response when administered with vehicle. This dose of clozapine did not disrupt PPI when administered with vehicle but did reverse the disruption in PPI induced by MK-801 (1 mg/kg).
DISCUSSION
The present results demonstrate that cannabidiol reverses MK-801-induced disruption of PPI. MK-801 dose-dependently disrupted PPI with a concomitant increase in the magnitude of the startle response at the lower and intermediate doses. Cannabidiol did not affect PPI when administered with vehicle alone, although it did increase the startle response. Cannabidiol reversed the disruption in PPI elicited by the highest dose of MK-801, an effect blocked by pretreatment with capsazepine prior to cannabidiol and MK-801. Clozapine also reversed the MK-801-induced disruption of PPI, while capsazepine alone did not. To our knowledge, this is the first report that cannabidiol can restore sensorimotor gating deficits induced by MK-801.
The disruption of PPI elicited by MK-801 is consistent with previous reports of MK-801-induced disruption of PPI in mice (Curzon and Decker, 1998; Sakaue et al, 2003; Yee et al, 2004) . It has been proposed that blockade of NMDA receptor-mediated transmission by noncompetitive antagonists such as MK-801 leads to excessive stimulation of non-NMDA glutamate-gated ion channels such as a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainic acid (KA) receptors via reduced stimulation of GABAergic interneurons and subsequent disinhibition of glutamatergic neurons (Deutsch et al, 2001 ). This effect may be manifest in schizophrenia as NMDA receptor hypofunction (NRH), leading not only to excitotoxic activation of AMPA/KA receptors but also to dysregulation of dopaminergic balance over the long term by diminishing cortical dopaminergic tone and thus increasing subcortical dopaminergic tone (Deutsch et al, 2001 ). However, modulation of dopaminergic activity is unlikely to be directly responsible for the disruptive effect of MK-801 on PPI, as MK-801 also disrupted PPI in wild-type and mutant D 1 and D 2 receptor knockout mice (Ralph-Williams et al, 2002) , and typical antipsychotics with dopamine antagonist profiles do not restore MK-801-induced deficits in sensorimotor gating (Curzon and Decker, 1998; Martin et al, 2003) . In the present study, the observation that the atypical antipsychotic clozapine restores MK-801-induced PPI disruption is in agreement with previous studies in rats and mice (Bakshi et al, 1994; Martin et al, 2003; Bubenikova et al, 2005) and provides a positive control for reversal of MK-801-induced sensorimotor gating deficits.
The startle response tended to be increased in some treatment groups such as the VEH1 þ CBD 5 þ MK 1 group. The effects of centrally active drugs on startle response and PPI in mice tend to be dissociated , reflecting the relative simplicity of the neurocircuitry of the startle response and the more complex neural mechanisms regulating PPI. This dissociation is reflected in our data, in which a slightly increased startle response and disrupted PPI was observed in the VEH1 þ VEH2 þ MK 1 group while a similarly increased startle response and normal PPI was observed in the VEH1 þ CBD 5 þ VEH3 group.
The restorative effect of cannabidiol on MK-801-induced disruption reflects an antipsychotic potential of cannabidiol. This is in keeping with similar indications observed in rats in which cannabidiol reversed apomorphine-induced stereotypy (Zuardi et al, 1991) and in a female schizophrenic patient in whom cannabidiol markedly reduced psychotic symptoms (Zuardi et al, 1995) . The dose range of cannabidiol (1, 5, and 15 mg/kg) used in the present study is lower than doses previously determined to reverse the effects of psychoactive drugs in rats (Zuardi et al, 1991; Moreira and Guimaraes, 2005) ; however, it has previously been shown to be active in extinguishing conditioned place preference learning induced by amphetamine and cocaine (Parker et al, 2004) . The lack of effect of either capsazepine or cannabidiol per se on PPI and startle response suggests that these drugs do not directly interfere with normal sensorimotor gating in the mouse. Importantly, the lack of effect of cannabidiol on startle reflects the comparative absence of sedative or cataleptic effects at these doses of cannabidiol.
There was no difference between the habituation observed in any of the treatment groups, suggesting that this form of startle response plasticity is not affected by TRPV1 or NMDA receptor antagonism or by cannabidiol in the present study. MK-801 has previously been reported to impair habituation in mice (Klamer et al, 2004) . It has been suggested that separating habituation test sessions comprising consecutive startling pulses by a PPI session consisting of both startling pulses and prepulses may influence the degree of habituation (Varty et al, 2000) . The present study used this experimental protocol which may explain the difference between the present results and the results of the Klamer et al study, which used a series of 121 consecutive pulse-alone trials.
In vitro studies have reported that cannabidiol has affinity for TRPV1 receptors and inhibits the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide (Bisogno et al, 2001) . Pretreatment with the TRPV1 receptor antagonist capsazepine prior to cannabidiol and MK-801 elicited a disruption of PPI similar to that observed with vehicle and MK-801 alone, suggesting that TRPV1 receptors may be involved in the restorative effect of cannabidiol on MK-801-induced disruption of PPI. However, although capsazepine has been shown to reverse capsaicin-induced effects such as dopaminergic cell death induced in vivo by intranigral injection (Kim et al, 2005) and to reverse antihyperalgesic effects of cannabidiol in rats (Costa et al, 2004) , it has also been shown to block calcium channels and nicotinic cholinergic receptors at the same doses at which it blocks the TRPV1 receptor (Docherty et al, 1997; Liu and Simon, 1997) , making it difficult to conclusively identify the involvement of TRPV1 receptors in the effect of cannabidiol in the present study. In preliminary experiments in our laboratory with systemic administration of the potent and selective TRPV1 antagonist iodoresiniferatoxin, hypomotility and accompanying hypothermia (unpublished observations) resulted in the startle response being too low for use in obtaining meaningful PPI data.
Following the detection of the expression of TRPV1 receptors in areas including the cortex, hippocampus, central amygdala, striatum, hypothalamus, substantia nigra, reticular formation and cerebellum (Mezey et al, 2000) and the localization of TRPV1 receptors on neurons, astrocytes, and pericytes (Toth et al, 2005) , interest in the role of TRPV1 receptors has broadened from a focus on their role in pain perception into consideration of their involvement in the control of emotions, learning, and satiety. These brain regions are also part of the circuitry regulating sensorimotor gating (Koch and Schnitzler, 1997; Swerdlow and Geyer, 1998) . From the observation that TRPV1 and tyrosine hydroxylase expression are colocalized in the substantia nigra, it was suggested that vanilloid-sensitive neurons are monoaminergic in this region (Mezey et al, 2000) . Expression of TRPV1 receptors on glutamatergic terminals is also likely as their activation produces glutamate release in the rat hypothalamus (Sasamura et al, 1998) , substantia nigra (Marinelli et al, 2003) , and substantia gelatinosa (Yue et al, 2004) . Further work has demonstrated that activation of TRPV1 receptors in the ventral tegmental area causes dopamine release in the nucleus accumbens, which may be due to increased glutamatergic transmission onto dopaminergic neurons (Marinelli et al, 2005) . The existence of TRPV1 receptors in brain regions involved in sensorimotor gating is in agreement with the results obtained in the present study.
Anandamide has been proposed as an endogenous TRPV1 receptor agonist (Szallasi and Di Marzo, 2000) . It activates TRPV1 receptors and facilitates neurotransmitter release (Zygmunt et al, 1999; Al-Hayani et al, 2001; Marinelli et al, 2003 ; for a review, see Ross, 2003) . The efficacy of anandamide as a TRPV1 agonist varies with receptor reserve, cellular uptake, fatty acid amide hydrolase (FAAH) and lipoxygenase metabolism, and protein signalling pathways (Ross, 2003; Van Der Stelt and Di Marzo, 2004) and may be increased in pathological conditions such as inflammation in which upregulation of TRPV1 receptors occurs. An entourage effect of N-acyl ethanolamides such as palmitoylethylamide coreleased with anandamide may facilitate the activity of anandamide at TRPV1 receptors Smart et al, 2002) . In the CNS, anandamide is present in brain regions expressing TRPV1 receptors including hippocampus and basal ganglia, regions also expressing high levels of CB 1 receptor, for which anandamide is also an endogenous agonist.
Retrograde signalling of endocannabinoids involves postsynaptic synthesis and release following depolarization of the postsynaptic terminal and diffusion across the synaptic cleft to bind to presynaptic CB 1 receptors (Wilson and Nicoll, 2001) . As the effect of anandamide on both TRPV1 and CB 1 receptors is regulated by FAAH hydrolysis and cellular uptake by the putative anandamide transporter (Hillard, 2000) , it is possible that inhibition of anandamide hydrolysis and reuptake by cannabidiol could lead to potentiation of the activity of anandamide at both TRPV1 and CB 1 receptors. Coexpression of CB 1 and TRPV1 receptors has been demonstrated in rat dorsal root ganglion neurons (Ahluwalia et al, 2000; Bridges et al, 2003) and in rat mesencephalic cultures (Kim et al, 2005) . Tonic activation of CB 1 receptors exerts an inhibitory control over TRPV1 receptors, as anandamide or capsaicin-induced TRPV1 receptor-mediated effects are potentiated in the presence of a CB 1 receptor antagonist (Maccarrone et al, 2000; Mang et al, 2001; Lever and Malcangio, 2002) . Furthermore, cell death induced by capsaicin and the CB 1 agonist HU-210 in rat mesencephalic culture was reversed by the CB 1 receptor antagonist AM 251 and capsazepine, respectively, suggesting functional crosstalk between the two receptors (Kim et al, 2005) . Cannabidiol produces TRPV1 activation at a nine-fold lower concentration than that at which it inhibits anandamide hydrolysis and at a seven-fold lower concentration than that at which it blocks cellular anandamide uptake (Bisogno et al, 2001) , thus CB 1 receptor-mediated effects resulting from inhibition of anandamide hydrolysis are likely to be counteracted by the direct activation of TRPV1 by cannabidiol. If cannabidiol exerted its effect on disrupted PPI in the present study via TRPV1 receptor activation, changes in mesolimbic glutamatergic and dopaminergic transmission may have occurred, thus counteracting the effect of NMDA receptor antagonism by MK-801.
The present results are of further interest in the context of the epidemiological relationship observed between cannabis consumption and schizophrenia. Individuals who consume cannabis are twice as likely to develop schizophrenia (Smit et al, 2004) , although evidence does not suggest that cannabis consumption independently precipitates schizophrenia, but that it may be a companion to a complex group of factors predisposing an individual to the development of the disease (Arseneault et al, 2004) . Thus although D
9
-THC and other psychotropic cannabinoids may be precipitating risk factors for schizophrenia, the present results provide scope for speculation on the potential role of the nonpsychotropic Cannabis constituent cannabidiol as an antipsychotic compound.
In summary, the present study is the first to investigate the effects of cannabidiol and capsazepine on PPI and suggests a promising avenue for investigation into the central effects of cannabidiol. The results indicate that cannabidiol reverses sensorimotor gating deficits induced by the NMDA receptor antagonist MK-801, and that this effect may be mediated by TRPV1 receptors as evidenced by the reversal of the effect of cannabidiol by capsazepine. Future studies using more selective ligands and several models of disrupted PPI will further elucidate the mechanism of the effects of cannabidiol on PPI.
